HLA-A*0201 & B2M & EBV LMP1 (YLLEMLWRL) 製品リスト
You Have Viewed 0 Of 0 Results
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| NGM-313 | NGM-313; MK-3655 | Phase 2 Clinical | Ngm Biopharmaceuticals Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Hepatitis; Obesity | 詳細 |
| Fazpilodemab | RG-7992; BFKB-8488A; RO-7040551 | Phase 1 Clinical | Genentech Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Insulin Resistance | 詳細 |
| B-1344 | B-1344 | Phase 1 Clinical | Tasly Biomedical Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2 | 詳細 |